As genomic analysis revealed that the UCC14 patient tumor and paired PDX harbored a hotspot mutation in ERBB2 (HER2 S310F), we sought to leverage this model to explore the biological basis for the limited anti-tumor activity of HER2-targeted therapies in patients with UC. Here, ERBB2 is linked to neoplasm.